Pharmaceutical company Moderna announced on March 7, 2022 that it would develop a site in Kenya to manufacture Covid-19 vaccines. The company holds much of the key intellectual property relating to the messenger RNA vaccines. Due to their higher efficacy, mRNA vaccines are the preferred option in developed countries. They account for 92% of all vaccinations to date in the US and European Union.
The Cape Town hub is supported by a range of partners who bring expertise, experience and resources, all of which are essential for a successful technology transfer. The idea of reproducing these key inputs at other sites seems counter-intuitive. Patents and profits in pharmaceuticals The decisions of the drug manufacturers are reminiscent of the struggle over patents for HIV drugs which took place in South Africa during the early 2000s.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: BusinessTechSA - 🏆 24. / 61 더 많은 것을 읽으십시오 »